In This SectionTexas Health Research & Education Institute
Disease or Condition
Venous Thromboembolism (VTE)
A Safety and Efficacy Trial of Apixaban for Prophylaxis of Venous Thromboembolism in Acutely Ill Medical Subjects During and Following Hospitalization (Venous Thromboembolism - VTE)
This is a randomized study comparing Lovenox (an FDA approved drug) with Apixaban (an investigational medicine) for acutely ill patients with a high risk of developing a blood clot. This study is 90 days in length.
Men and non-pregnant, non-brestfeeding women ages 40 years or older.
Patients hospitalized with congestive heart failure or acute respiratory failure.
Patients with an infection (without septic shock).
Patient with acute rheumatoid disorder.
Patients with inflammatory bowel disease.
Patients with a detected blood clot, pregnant, abnormal liver or kidney blood tests, or who currently require long term anti-coagulation medications are not eligible for this study.
Patients who have a bleeding disorder or other serious illnesses may not be eligible to participate.